Dialysis Adequacy and Response to Erythropoiesis-Stimulating Agents: What Is the Evidence Base?

Seminars in Nephrology

Volumn 26, Issue 4, 2006, Pages 269-274

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^b   Pozzoni, Pietro ^a   Andrulli, Simeone ^a  

^a A MANZONI HOSPITAL   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

anemia; convective treatments; daily hemodialysis; dialysate; dialysis dose; hemodialysis; membrane; on line treatments

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; UREMIC TOXIN;

ANEMIA; ARTICLE; BIOCOMPATIBILITY; CYTOKINE PRODUCTION; DIALYSATE; DIALYSIS; DIALYSIS MEMBRANE; DRUG RESPONSE; ERYTHROPOIESIS; EVIDENCE BASED MEDICINE; HEMATOCRIT; HEMODIAFILTRATION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; IRON DEPLETION; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANEMIA; ANIMALS; DRUG CONTAMINATION; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; EVIDENCE-BASED MEDICINE; HEMODIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TOXINS, BIOLOGICAL;

EID: 33750894789     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.05.002     Document Type: Article

References (47)

1. Kuroyanagi T., and Saito M. Presence of toxic substances which inhibit erythropoiesis in serum of uremic nephrectomized rabbits. Tohoku J Exp Med 88 (1966) 117-126
2. Segal G.M., Stueve T., and Adamson J.W. Spermine and spermidine are non-specific inhibitors of in vitro hematopoiesis. Kidney Int 31 (1987) 72-76
3. Galli F., Beninati S., Benedetti S., et al. Polymeric protein-polyamine conjugates: A new class of uremic toxins affecting erythropoiesis. Kidney Int Suppl 78 (2001) S73-S76
4. Kawashima Y., Sanaka T., Sugino N., et al. Suppressive effect of quinolinic acid and hippuric acid on bone marrow erythroid growth and lymphocyte blast formation in uremia. Adv Exp Med Biol 223 (1987) 69-72
5. Pawlak D., Koda M., Pawlak S., et al. Contribution of quinolinic acid in the development of anemia in renal insufficiency. Am J Physiol 284 (2003) F693-F700
6. Stenvinkel P., Heimburger O., Paultre F., et al. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 55 (1999) 1899-1811
7. Barany P., Divino Filho J.C., and Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29 (1997) 565-568
8. Gunnell J., Yeun J.Y., Depner T.A., et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33 (1999) 63-72
9. Locatelli F., Andrulli S., Memoli B., et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 21 (2006) 991-998
10. Panichi V., Migliori M., De Pietro S., et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 91 (2002) 594-600
11. Kalantar-Zadeh K., Kopple J.D., Humphreys M.H., et al. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 1507-1519
12. Jongen-Lavrencic M., Peeters H.R.M., Rozemuller H., et al. IL-6 induced anaemia in rats: Possible pathogenetic implications for anaemia observed in chronic inflammations. Clin Exp Immunol 103 (1996) 328-334
13. Shooley J.C., Kullgren B., and Allison A.C. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 67 (1987) 11-17
14. Goicoechea M., Martin J., de Sequera P., et al. Role of cytokines in the response to erythropoietin in haemodialysis patients. Kidney Int 54 (1998) 1337-1343
15. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42 (2003) 761-773
16. Allen D.A., Breen C., Yaqoob M.M., et al. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: Role of IFN-gamma and TNF-alpha. J Investig Med 47 (1999) 204-211
17. Bologa R., Levine D., Parker T., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia and mortality in haemodialysis patients. Am J Kidney Dis 54 (1998) 245-254
18. Pontoriero G., Andrulli S., Conte F., et al. Microbial contamination in water and dialysate: A prospective multicenter study. Nephrol Dial Transplant 17 suppl 1 (2002) A152
19. Ifudu O., Feldman J., and Friedman E.A. The intensity of haemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334 (1996) 420-425
20. Ifudu O., Uribarri J., Rajwani I., et al. Adequacy of dialysis and differences in haematocrit among dialysis facilities. Am J Kidney Dis 36 (2000) 1166-1174
21. Madore F., Lowrie E.G., Brugnara C., et al. Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8 (1997) 1921-1929
22. Coladonato J.A., Frankenfield D.L., Reddan D.N., et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 13 (2002) 1288-1295
23. Katzarski K.S., Charra B., Luik A.J., et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 14 (1999) 369-375
24. Movilli E., Cancarini G.C., Zani R., et al. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently form the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 16 (2000) 111-114
25. Kobayashi H., Ono T., Yamamoto N., et al. Removal of high molecular weight substances with large pore size membrane (BK-F). Kidney Dialysis 34 suppl (1993) 154-157
26. Villaverde M., Pérez-Garcia R., Verde E., et al. La polisulfona de alta permeabilidad mejora la respuesta de la anemia a la eritropoyetina en hemodialisis. Nefrologia 19 (1999) 161-167
27. Yamada S., Kataoka H., Kobayashi H., et al. Identification of an erythropoietic inhibitor from the dialysate collected in the hemodialysis with PMMA membrane (BK-F). Contrib Nephrol 125 (1999) 159-172
28. Locatelli F., Mastrangelo F., Redaelli B., et al., The Italian Cooperative Dialysis Study Group. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 50 (1996) 1293-1302
29. Locatelli F., Andrulli S., Pecchini F., et al. Effect of high-flux dialysis on the anemia of haemodialysis patients. Nephrol Dial Transplant 15 (2000) 1399-1409
30. Basile C., Giordano R., Montanaro A., et al. Effect of acetate-free biofiltration on the anemia of haemodialysis patients: A prospective cross-over study. Nephrol Dial Transplant 16 (2001) 1914-1919
31. Opatrny Jr. K., Reischig T., Vienken J., et al. Does treatment modality have an impact on anemia in patients with chronic renal failure?. Effect of low- and high-flux biocompatible dialysis. Artif Organs 26 (2002) 181-188
32. Richardson D., Lindley E.J., Bartlett C., et al. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response. Am J Kidney Dis 42 (2003) 551-560
33. Maduell F., del Pozo C., Garcia H., et al. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 14 (1999) 1202-1207
34. Bonforte G., Grillo P., Zerbi S., et al. Improvement of anemia in haemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid. Blood Purif 20 (2002) 357-363
35. Lin C.L., Huang C.C., Yu C.C., et al. Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. Blood Purif 20 (2002) 349-356
36. Vaslaki L., Major L., Berta K., et al. On-line haemodiafiltration versus haemodialysis: Stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif 24 (2006) 163-173
37. Ward R.A., Schmidt B., Hullin J., et al. A comparison of on-line hemodiafiltration and high flux haemodialysis: A prospective clinical study. J Am Soc Nephrol 11 (2000) 2344-2350
38. Wizemann V., Lotz C., Techert F., et al. On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomised study. Nephrol Dial Transplant 15 suppl 1 (2000) 43-48
39. Sitter T., Bergner A., and Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15 (2000) 1207-1211
40. Schiffl H., Lang S.M., Stratakis D., et al. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 16 (2001) 1863-1869
41. Fagugli R.M., Buoncristiani U., and Ciao G. Anaemia and blood pressure correction obtained by daily haemodialysis induce a reduction of left ventricular hypertrophy in dialysed patients. Int J Artif Organs (1998) 429-431
42. Klarenbach S., Heidenheim A.P., Leitch R., et al. The Daily/Nocturnal Dialysis Study Group: Reduced requirement for erythropoietin with quotidian haemodialysis therapy. ASAIO J 48 (2002) 57-61
43. Walsh M., Culleton B., Tonelli M., et al. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 67 (2005) 1500-1508
44. Chan C.T., Schwartz D., Pierratos A., et al. Impact of nocturnal home hemodialysis on anemia management in end-stage renal disease patients. J Am Soc Nephrol 14 (2003) 498A (abstr)
45. Chan C., Floras J.S., Miller J.A., et al. Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant 17 (2002) 1518-1521
46. Rao M., Muirhead N., Klarenbach S., et al. Management of anemia with quotidian hemodialysis. Am J Kidney Dis 42 (2003) 18-22
47. Jaber B.L., Zimmerman D.L., Teehan G.S., et al. Daily Hemofiltration for End-Stage Renal Disease: A feasibility and efficacy trial. Blood Purif 22 (2004) 481-489